Advertisement

The History of l-Deprenyl

  • M. J. Parnham
Chapter
Part of the Milestones in Drug Therapy book series (MDT)

Abstract

The above statement was quoted first to me many years ago by Iván Bonta during a successful four-year period I spent in his department in Rotterdam. It is particularly apt as the opening sentence to a history of l-deprenyl, since it was first said by a Hungarian Nobel Prizewinner, quoted to me by an ex-Hungarian emigré, and summarizes very succinctly the story of a Hungarian drug, published in a book by a Germano-Hungarian editor! But the history of l-deprenyl is much more than a parochial Hungarian affair; its see-saw fortunes have carried it on a roller-coaster developmental journey through many countries over 30 years. At each stage there have been a few clear thinkers who, while seeing the facts at their and others’ disposal, still managed to think what others had not thought.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Dow A. The Deprenyl Story. Toronto: Stoddart, 1990.Google Scholar
  2. [2]
    Zeller EA. Monoamine oxidase and its inhibitors in relation to antidepressive activity. In: Parnham MJ, Bruinvels J, editors. Psycho- and Neuropharmacology. Discoveries in Pharmacology. Vol. 1. Amsterdam: Elsevier, 1983: 223–232.Google Scholar
  3. [3]
    Lehmann HE, Kline NS. Clinical discoveries with anti-depressant drugs: In: Parnham MJ, Bruinvels J, editors. Psycho- and Neuro-pharmacology. Discoveries in Pharmacology. Vol. 1. Amsterdam: Elsevier, 1983: 209–222.Google Scholar
  4. [4]
    Schier O, Marxer A. Antihypertensive agents 1962–1968: Progr Drug Res 1969; 13: 101–135.Google Scholar
  5. [5]
    Knoll J. Deprenyl (selegiline): the history of its development and phamacological action. Acta Neurol Scand, 1983; [Supplement] 95: 57–80.CrossRefGoogle Scholar
  6. [6]
    Knoll J, Ecseri Z, Kelemen K, Nievel J, Knoll B. Phenyl-isopropylmethylpropinylamine (E-250), a new spectrum psychic energizer. Arch Int Pharmacodyn 1965; 155: 154–164.Google Scholar
  7. [7]
    Ecseri Z, Müller M, Knoll J, Somfai E. Hungarian Patent Nr. 151090, 1964.Google Scholar
  8. [8]
    Varga A, Tringer L. Clinical trial of a new type of promptly acting psychoenergetic agent (phenyl-isopropyl-methyl-propinylamine-HCl) (E-250). Acta Med Acad Sci Hung 1967; 23: 289–295.Google Scholar
  9. [9]
    Magyar K, Vizi ES, Ecseri Z, Knoll J. Comparative pharmacological analysis of the optical isomers of phenyl-isopropyl-methyl-propinylamine (E-250). Acta Physiol Acad Sci Hung 1967; 32: 377–387.Google Scholar
  10. [10]
    Hardegg W, Heilbron E. Oxidation of tyramine and serotonin by liver mitochondrial monoamine oxidase. Biochim Biophys Acta 1961; 51: 533–559.Google Scholar
  11. [11]
    Johnston JP. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 1968; 17: 1285–1297.CrossRefGoogle Scholar
  12. [12]
    Youdim MBH, Finberg JPM. Monoamine oxidase B inhibition and the “cheese effect”. J Neural Transm 1987; [Supplement] 25: 27–33.Google Scholar
  13. [13]
    Knoll J, Vizi ES, Somogyi G. Phenylisopropyl-methyl-propinylamine (E-250), a monoamine oxidase inhibitor antagonizing effects of tyramine. Arzn-Forsch 1968; 18: 109–112.Google Scholar
  14. [14]
    Knoll J, Magyar K. Some puzzling effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 1972; 5: 393–408.Google Scholar
  15. [15]
    Collins GGS, Sandler M, Williams ED, Youdim MBH. Multiple forms of human brain mitochondrial monoamine oxidase. Nature 1970; 225: 817–820.CrossRefGoogle Scholar
  16. [16]
    Squires R. Multiple forms of monoamine oxidase in intact mitochondria as characterized by selective inhibitors and thermal stability. A comparison of eight mammalian species. Adv Biochem Psychopharmacol 1972; 5: 355–370.Google Scholar
  17. [17]
    Knoll J. Analysis of the pharmacological effects of selective monoamine oxidase inhibitors. In: Wolstenholme GEW, Knight J, editors: Monoamine oxidase and its inhibition. Amsterdam: Elsevier 1976: 135–161.Google Scholar
  18. [18]
    Carlsson A. Antipsychotic agents: elucidation of their mode of action. In: Parnham MJ, Bruinvels J, editors. Psycho- and Neuro-pharmacology. Discoveries in Pharmacology. Vol. 1. Amsterdam: Elsevier 1983: 197–206.Google Scholar
  19. [19]
    Birkmayer W. 10 Jahre L-DOPA-Therapie des Parkinson-Syndroms. Wien Klin Wschr 1971; 83: 221–227.Google Scholar
  20. [20]
    Birkmayer W, Hornykiewicz O. Der L-Dioxyphenylalanin (l-DOPA) Effekt bei der Parkinson-Akinesie. Wien Klin Wschr 1961; 73: 787–794.Google Scholar
  21. [21]
    Riederer P. Besuch beim “Heurigen” brachte den entscheidenden Entschluß. In: Morbus Parkinson. Eine Dokumentation der Ärzte Zeitung 1991: 20–22.Google Scholar
  22. [22]
    Birkmayer W, Riederer P, Youdim MBH, Linauer W. Potentiation of anti-akinetic effect after L-dopa treatment by an inhibitor of MAO-B, l-deprenyl. J Neural Transm 1975; 36: 303–323.CrossRefGoogle Scholar
  23. [23]
    Birkmayer W, Riederer P, Ambrozi L, Youdim MBH. Implications of combined treatment with Madopar and l-deprenyl in Parkinson’s disease. Lancet 1977; ii: 439–443.CrossRefGoogle Scholar
  24. [24]
    Lees AJ, Shaw KM, Kohout LJ, Stern GM, Elsworth JD, Sandler M, Youdim MBH. Deprenyl in Parkinson’s disease. Lancet 1977; ii: 791–796.CrossRefGoogle Scholar
  25. [25]
    Waldholz M. Medical Odyssey. The Wall Street Journal 1990 Nov 28; p. 1 (col. 1).Google Scholar
  26. [26]
    Markey SP, Schmuff NR. The pharmacology of the parkinsonian syndrome producing neurotoxin MPTP (l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine) and structurally related compounds. Med Res Rev 1986; 6: 389–429.CrossRefGoogle Scholar
  27. [27]
    Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in human due to a product of meperidine-analog synthesis. Science 1983; 219: 979–980.CrossRefGoogle Scholar
  28. [28]
    Ceballos I, Javoy-Agid F, Delacourte A, Defossez A, Nicole A, Sinet P-M. Parkinson’s disease and Alzheimer’s disease: neurodegenerative disorders due to brain antioxidant deficiency? Adv Exp Med Biol 1990; 264: 493–498.CrossRefGoogle Scholar
  29. [29]
    Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Marton J. Increased life expectancy resulting from addition of l-deprenyl to Madopar treatment in Parkinson’s disease: a longterm study. J Neural Transm 1985; 64: 113–127.CrossRefGoogle Scholar
  30. [30]
    Press release. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; 1991 Nov 5–7; Brussels.Google Scholar
  31. [31]
    Golbe LI, Liebermann AN, Muenter MD, Ahlskog J, Gopinathan G, Neophytides AN, Foo SH, Duvoisin RC. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson’s disease. Clin Neuropharmacol 1988; 11: 45–55.CrossRefGoogle Scholar

Copyright information

© Springer Basel AG 1993

Authors and Affiliations

  • M. J. Parnham

There are no affiliations available

Personalised recommendations